Back to Journals » OncoTargets and Therapy » Volume 11

Downregulation of miR-638 promotes progression of breast cancer and is associated with prognosis of breast cancer patients

Authors Li M, Wang J, Liu H

Received 31 July 2018

Accepted for publication 4 September 2018

Published 12 October 2018 Volume 2018:11 Pages 6871—6877

DOI https://doi.org/10.2147/OTT.S182034

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Sanjeev Srivastava


Minghong Li,* Jian Wang,* Haibo Liu

Department of Laboratory Medicine, Yidu Central Hospital of Weifang, Shandong 262500, People’s Republic of China

*These authors contributed equally to this work

Background: Breast cancer is the most common tumor among women. miR-638 has been demonstrated to play an important role in various cancers.
Purpose: In this study, we aimed to investigate the function and prognostic value of miR-638 in breast cancer.
Methods: Quantitative real-time polymerase chain reaction analysis was used to evaluate the expression of miR-638 in breast cancer tissues and cell lines. The correlation of miR-638 with clinicopathological features was analyzed using the chi-squared test. Kaplan–Meier survival analysis and Cox regression assay were performed to investigate the prognostic value of miR-638 in breast cancer patients. The effects of miR-638 on the biological behavior of breast cancer cells were evaluated using functional assays.
Results: The expression of miR-638 was downregulated in breast cancer tissues and cell lines (all P<0.05). Decreased expression of miR-638 was significantly correlated with lymph node metastasis (P=0.015) and TNM stage (P=0.021). Patients with low miR-638 expression had shorter overall survival compared with those with high levels (Log-rank P=0.025). The miR-638 could be considered as an independent prognostic factor for the patients (HR =0.321, 95% CI =0.117–0.882, P=0.027). Downregulation of miR-638 was capable of promoting cell proliferation, migration, and invasion in MDA-MB-231 and MCF-7 cells.
Conclusion: All the results indicate that miR-638 is a tumor suppressor in breast cancer and is involved in the progression of breast cancer. Thus, it may serve as a prognostic biomarker for breast cancer.

Keywords: miR-638, cell proliferation, migration, invasion, prognosis, breast cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]